ImCheck Therapeutics clinical trials
Acquired by Ipsen, Dec 15, 2025 · source ↗
The registry lists 2 studies whose lead sponsor is ImCheck Therapeutics. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 4, 2026.
Before and after it joined Ipsen
- First submitted before ImCheck Therapeutics became part of Ipsen
- 2
- First submitted after ImCheck Therapeutics became part of Ipsen
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- ImCheck Therapeutics, an Ipsen company2 studies
Something wrong with this grouping? Tell us on the Ipsen page.
Studies
Recruiting first, then most recently updated. Showing 2 of 2. All Ipsen studies →
- First-in-Human Study of ICT01 in Patients With Advanced CancerActive, not recruitingNCT04243499Phase 1/2
Sponsor listed in the registry: ImCheck Therapeutics, an Ipsen company · First submitted before ImCheck Therapeutics became part of Ipsen
- Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid TumorsTerminatedNCT05307874Phase 1/2
Sponsor listed in the registry: ImCheck Therapeutics, an Ipsen company · First submitted before ImCheck Therapeutics became part of Ipsen